STOK.US Stoke Therapeutics Inc

Healthcare Biotechnology USA Stocks
26.41 USD
Close of Nov 18, 2026
22.05 40.22
Market cap
USD 1.73B
P/E
-
P/B
4.94x
ROE
-70.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is STOK.US undervalued?

Graham number

The Graham number of Stoke Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Stoke Therapeutics Inc fundamental analysis

No fundamental analysis for Stoke Therapeutics Inc yet.

Stoke Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001),…

Full company profile